FLORHAM PARK, N.J., March 10, 2022 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced the company will participate and be available for 1×1 meetings at the following upcoming conferences:
|
Roth Capital Partners 34 th Annual Conference |
|
| Date: | March 15, 2022 |
| Time: | 10:00 am PT / 1:00 pm ET |
| Format: | Fireside chat and available for 1×1 investor meetings |
|
Oppenheimer 32 nd Annual Healthcare Conference |
|
|
Date : |
March 16, 2022 |
| Time: | 3:20 pm ET |
| Format: | Virtual presentation and available for 1×1 investor meetings |
| Webcast: |
To register, click on the link HERE |
A replay of the Oppenheimer presentation will be available on the
Investor page
of the company website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.
The company’s product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), and proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. The company is currently investigating iopofosine in a global, pivotal expansion cohort in relapsed or refractory Waldenstrom’s macroglobulinemia (WM) patients who have received at least two prior lines of therapy, including those who have failed or had a suboptimal response to Bruton tyrosine kinase inhibitors (BTKi). The WM cohort will enroll up to 50 patients to evaluate the efficacy and safety of iopofosine for marketing approval. The company is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase 2 CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase 1 CLOVER-2 study.
The Phase 1 pediatric study is an open-label, sequential-group, dose-escalation study to evaluate the safety and tolerability of iopofosine in children and adolescents with relapsed or refractory cancers, including malignant brain tumors, neuroblastoma, sarcomas, and lymphomas (including Hodgkin’s lymphoma). The Phase 1 study is being conducted internationally at seven leading pediatric cancer centers.
For more information, please visit
www.cellectar.com
and
www.wmclinicaltrial.com
or join the conversation by liking and following us on the company’s social media channels:
Twitter
,
LinkedIn
, and
Facebook
.
Contacts
Investors:
Monique Kosse
Managing Director
LifeSci Advisors
212-915-3820
[email protected]
